Kodiak Sciences Inc
KOD9.840USD
+0.630+6.84%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
519.77MMarket Cap
LossP/E TTM
More Details of Kodiak Sciences Inc Company
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Company Info
Ticker SymbolKOD
Company nameKodiak Sciences Inc
IPO dateOct 04, 2018
CEODr. Victor Perlroth, M.D.
Number of employees109
Security typeOrdinary Share
Fiscal year-endOct 04
Address1250 Page Mill Road
CityPALO ALTO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94304
Phone16502810850
Websitehttps://kodiak.com/
Ticker SymbolKOD
IPO dateOct 04, 2018
CEODr. Victor Perlroth, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
32.77%
Perlroth (Victor D)
5.10%
BlackRock Institutional Trust Company, N.A.
5.08%
Adage Capital Management, L.P.
3.89%
Acadian Asset Management LLC
3.73%
Other
49.42%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
32.77%
Perlroth (Victor D)
5.10%
BlackRock Institutional Trust Company, N.A.
5.08%
Adage Capital Management, L.P.
3.89%
Acadian Asset Management LLC
3.73%
Other
49.42%
Shareholder Types
Shareholders
Proportion
Hedge Fund
45.58%
Investment Advisor
18.13%
Investment Advisor/Hedge Fund
13.82%
Individual Investor
5.52%
Endowment Fund
1.31%
Research Firm
0.36%
Pension Fund
0.14%
Venture Capital
0.08%
Bank and Trust
0.08%
Other
14.99%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
273
46.04M
87.25%
-8.67M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
2023Q3
391
45.97M
87.64%
-8.18M
2023Q2
401
46.07M
88.00%
-6.85M
2023Q1
414
44.84M
85.66%
-7.92M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
17.31M
32.81%
--
--
Mar 31, 2025
Perlroth (Victor D)
2.70M
5.11%
+527.00K
+24.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.37%
-21.30K
-0.75%
Mar 31, 2025
Adage Capital Management, L.P.
1.33M
2.51%
+186.18K
+16.34%
Mar 31, 2025
Acadian Asset Management LLC
1.95M
3.69%
+413.82K
+27.01%
Mar 31, 2025
The Vanguard Group, Inc.
1.69M
3.2%
+6.61K
+0.39%
Mar 31, 2025
ICONIQ Capital, LLC
1.27M
2.4%
+249.70K
+24.56%
Mar 31, 2025
TCG Crossover Management, LLC
1.15M
2.17%
--
--
Mar 31, 2025
State Street Global Advisors (US)
849.25K
1.61%
+18.08K
+2.18%
Mar 31, 2025
Geode Capital Management, L.L.C.
793.59K
1.5%
+24.90K
+3.24%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Biotechnology ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Enhanced US All-Cap Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Fidelity Enhanced US All-Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
